pharma · Ovarian Neoplasms · Stage 3 or 4 Non-mucinous Epithelial Ovarian Cancer
TESARO Bio Netherlands
TESARO Bio Netherlands B.V.
TESARO Bio Netherlands clinical programs — 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- EU
- Programs
- 6
- Drugs
- 23
- Patents
- 0
TESARO Bio Netherlands projects
3 ClinicalTrials.gov programs sponsored by TESARO Bio Netherlands.
TESARO Bio Netherlands has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
213350/3000-03-005
TESARO Bio Netherlands B.V.
Stage 3 or 4 Non-mucinous Epithelial Ovarian Cancer
1 trial -
4010-03-001
TESARO Bio Netherlands B.V.
Recurrent or primary advanced (Stage III or IV) endometrial cancer
1 trial -
PR-30-5017-C
TESARO Bio Netherlands B.V.
Homologous recombination deficiency advanced ovarian cancer
1 trial
Frequently asked questions
How many clinical projects does TESARO Bio Netherlands have?
3 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.